NEBULA
Enabling the Undruggable

Physics-driven generative AI platform

NEBULA’s dataset-free AI technology unlocks targets that have long been labeled undruggable, we fast-track novel therapies

Contact us !

The Drug Discovery’s 80 % blind spot

Only 20 % of the ~5,000 identified therapeutic protein targets are currently “druggable.”
80 % remain undruggable, blocking innovation and driving late-stage failures, while competition for the small slice grows fiercer.

Harnessing the capabilities of dataset-free Generative AI to tackle undruggable drug targets

NEBULA GenAI Conf

Uncovers the full conformational landscape of a drug target at ultra-high atomic resolution, revealing cryptic binding pockets, novel allosteric sites, and the mechanism of the target itself — critical for the Market Approval process.

NEBULA GenAI New Molecule

Generates entirely unseen, novel drug-like molecules that bind selectively to a chosen drug target.

NEBULA Binding AI

Predicts binding strength with experimental accuracy — confirming potency before a molecule is ever synthesized.

NEBULA SCREEN AI

Screens every candidate for non-toxicity, ADME compliance, and synthesizability — before any wet-lab investment is made.

NEBULA’s platform maps dynamic 3-D conformations, generates novel drug-like molecules, predicts binding strength before synthesis, matches candidates to existing compounds for rapid repurposing, and screens for non-toxicity, ADME adherence, and synthesizability, unlocking medicines for diseases long viewed as undruggable.

Meet the TEAM

See who is behind the company

Daniel Wiczew

An entrepreneur with deep expertise in artificial intelligence, biomedical sciences, and drug design. Daniel brings unparalleled technical knowledge to NEBULA, driving our technology’s development and application in drug discovery.

Mounir Tarek

A senior research director with extensive experience in molecular modeling and computational biophysics. Mounir leads NEBULA with a vision to transform the pharmaceutical industry through innovative AI technologies.

Fabrice Balavoine

An accomplished biotech executive with over 20 years of leadership in drug discovery and pharmaceutical development. Fabrice drives NEBULA’s commercial growth by securing strategic partnerships and leveraging his proven success.

SPECIAL THANKS TO